Literature DB >> 1089401

Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol.

B Shopsin, S Gershon, H Thompson, P Collins.   

Abstract

Lithium carbonate, haloperidol, and chlorpromazine hydrochloride were compared in a double-blind controlled study with severely ill hospitalized manics. Lithium carbonate and haloperidol produced a highly significant improvement of manic symptoms without sedation. Although producing considerable sedation, chlorpromazine did little to alter the underlying mania qualitatively. Qualitative differences between lithium carbonate and haloperidol indicate that, while haloperidol has a more dramatically rapid impact on behavior-motor activity, lithium carbonate acted more evenly on the entire manic picture, with total normalization realized during active treatment. The majority of lithium carbonate-treated patients met discharge criteria at study termination, but not the patients receiving either neuroleptic drug. The rating scales are not sensitive enough to monitor manic psychopathology; this accounts for the lack of statistically significant differences among drug groups at treatment termination, despite the widely disparate discharge rates.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1089401     DOI: 10.1001/archpsyc.1975.01760190036004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  21 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

2.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 4.  Review of clinically important drug interactions with lithium.

Authors:  N S Harvey; S Merriman
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

5.  Haloperidol and lithium blocking of the mood response to intravenous methylphenidate.

Authors:  D Wald; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

Review 6.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  A comparative study of side-effects of lithium, carbamazepine and haloperidol in acute mania.

Authors:  J K Trivedi; A Lata; P K Dalal; P K Sinha; S Srivastava
Journal:  Indian J Psychiatry       Date:  1996-10       Impact factor: 1.759

Review 8.  Lithium in bipolar disorder: can drug concentrations predict therapeutic effect?

Authors:  Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.

Authors:  André R Brunoni; Laura Tadini; Felipe Fregni
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

10.  The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans.

Authors:  R H Belmaker; R P Ebstein; H Schoenfeld; R Rimon
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.